Klaria Pharma Q4: Transforming licensing deal - Redeye

Redeye leaves a research update following Klaria Pharma’s recently published Q4 2024 report. The main focus has been on the licensing agreement with CNX Therapeutics for the marketing and sale of its Sumatriptan Alginate Film in Europe. We are encouraged by this achievement and believe that it has provided Klaria with some much-needed short-term financing, extending its financial runway, while enabling a market launch already in H2 2025.

Länk till analysen i sin helhet: https://www.redeye.se/research/1084996/klaria-pharma-q4-transforming-licensing-deal?utm_source=finwire&utm_medium=RSS